Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Different Antiviral Strategies on Tumor Prognosis in Patients With HBV-related Liver Cancer After Radical Treatment: A Prospective, Open-label, Non-randomized Clinical Study

NCT07120750 is registered in ClinicalTrials.gov with Shenzhen Third People's Hospital as lead sponsor.

NCT NCT07120750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07120750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Different Antiviral Strategies on Tumor Prognosis in Patients With HBV-related Liver Cancer After Radical Treatment: A Prospective, Open-label, Non-randomized Clinical Study
Lead sponsor
Shenzhen Third People's Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 31, 2030
Enrollment
332 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b, hepatocellular carcinoma (hcc)